With many people on holiday right now, it’s good time to take stock of 2026 so far and look ahead to the rest of the year. The first half of 2026 has been really strong. The XBI index gained 23% and – more pertinently for privately-held biotechs – there was huge amounts of M&A going on. From January to June there were 33 deals worth more than $1 billion – according to Drug Discovery News – including three […]
Investment firms British Business Bank commits €25 million to EQT Life Science’s Health Economics 3 Fund dedicated to commercial stage medtech and digital health technologies Andera Partners raised €430 million for its Ander Expansion IV fund to invest in companies leading the way on ESG issues Asabys Partners joined The European Life Science Coalition (ELSC) as an Associate Member, alongside existing members Novo Holdings, Sofinnova Partners, […]
Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter Barcelona, Spain and Düsseldorf, Germany – 24 July, 2026 – Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional […]
Continued momentum in Poolbeg’s global intellectual property strategy 21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent […]
Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). […]
